COVID-19, caused by the severe acute respiratory syndrome corona virus 2 (SARS-CoV-2), was declared a pandemic by the World Health Organization on March 9, 2020. Hematopoietic stem-cell transplantation (HSCT) recipients may be highly susceptible to infection and related pulmonary complications due to nascent immune systems or organ damage from treatment-related toxicities. Poor outcomes in such group of patients were linked to older age, steroid therapy at the time of COVID-19 infection, and COVID-19 infection within a year of HSCT. We studied a cohort of 28 hematopoietic stem cell transplant recipients (male 17, M:F ratio of 1.5) with COVID-19 infection from 1st June 2020, through 31st December 2020 for outcome. Fever was the most common symptom at the time of presentation in 22 (78.5%) patients. Mortality rate at Day 28 and Day 42 was found to be 4/28 (14.3%) and 7/28 (25%) respectively. Patients within one year of HSCT and severe infection had higher day 28 mortality (with p values = 0.038)". There was no relation of mortality with type of transplant.

由严重急性呼吸综合征冠状病毒 2 (SARS-CoV-2) 引起的 COVID-19 于 2020 年 3 月 9 日被世界卫生组织宣布为大流行病。造血干细胞移植 (HSCT) 接受者可能高度易感由于新生免疫系统或治疗相关毒性引起的器官损伤引起的感染和相关肺部并发症。此类患者的不良结果与年龄较大、感染 COVID-19 时的类固醇治疗和 HSCT 一年内的 COVID-19 感染有关。我们研究了从 2020 年 6 月 1 日到 2020 年 12 月 31 日期间感染 COVID-19 的 28 名造血干细胞移植受者（男性 17 岁，男女比为 1.5）的队列，以了解结果。发热是 22 名 (78.5%) 患者就诊时最常见的症状。第 28 天和第 42 天的死亡率分别为 4/28 (14.3%) 和 7/28 (25%)。HSCT 一年内和严重感染的患者第 28 天死亡率较高（有p值 = 0.038)"。死亡率与移植类型无关。